Skip to main content
. 2017;5(1):25–34.

Figure 1.

Figure 1

[Histograms shows distribution of survival subgroups determined with the Prognostic Index for Spine Metastasis (PRISM) model among the (A) training set (205 patients treated on-protocol) and the (B) validation set (249 patients treated off-protocol).]